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OBJECTIVE
To describe the clinical cardiac manifestations and
temporal evolution of Marfan syndrome in children; to
estimate the incidence of annuloaortic ectasia and mitral
valve prolapse; and to evaluate tolerability and efficacy
of beta-blockers in these patients.
METHODS
During one year, 21 children with Marfan syndrome
underwent serial clinical and echocardiographic
examinations. Echocardiograms assessed: the presence
of mitral valve prolapse, aortic root diameter, mitral and
aortic valves regurgitation, and aortic enlargement during
beta-blocker therapy. Eleven patients had two
measurements of the aortic root taken one year apart.
RESULTS
The children were asymptomatic throughout the study.
Mitral prolapse was found in 11 (52%) children.
Annuloaortic ectasia occurred in 16 (76%) patients and
found to be mild in 42.8%, moderate in 9.5%, and severe
in 23.8%. One of these patients underwent aortic valve
replacement and repair of the ascending aorta by the
Bentall-De Bono technique, with good results. Heart rate
decreased by 13.6% (from 85 to 73 bpm; p < 0.009)
with the use of beta-blockers; however, aortic root diameter
increased by 1.4 mm/year (p<0.02). One child could not
be given beta-blockers due to bronchial asthma, and no
significant side effects were observed in the remaining
children, including one who also had bronchial asthma.
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CONCLUSION
The children remained asymptomatic throughout the
study, the use of beta-blockers led to a significant decrease
in heart rate, and no significant adverse effects were
observed. Contrary to the literature, incidence of
annuloaortic ectasia was high among the study
population, greater than that of mitral valve prolapse,
even during beta-blocker therapy.
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The Marfan syndrome is named after Antoine Marfan,
a French pediatrician who in 1896 presented the case of
a 5-year-old girl to the Societé Médicale des Hôpitaux in
Paris1.  Clinical characteristics and natural history of the
disease were described for the first time, in an ordered
manner, by McKusick in 19552. Marfan syndrome is an
inherited autosomal dominant disorder of the connective
tissue, with variable expression, which affects primarily
the skeletal, ocular and cardiovascular systems. Its
prevalence is estimated at about 1/10,000 individuals.
However, other estimates suggest higher figures ranging
from 4 to 6/10,000 individuals3. Marfan syndrome results
from mutations in the fibrillin 1 gene (FBN1)4. The primary
cardiovascular changes are annuloaortic ectasia and mitral
valve prolapse. Owing to these changes, life expectancy
of patients with Marfan syndrome just a few years ago
was up to the third or forth decade of life5, but a greater
knowledge of the disease and the advent of surgical tech-
niques in the last years led to a significant improvement
in prognosis6.
Most papers published in the literature describe adult
patients2-7,8; however, pediatric population is not free from
complications. Therefore, the aim of the present study is
threefold: to describe the clinical cardiac manifestations
and temporal evolution of Marfan syndrome in children;
to estimate the incidence of annuloaortic ectasia and
mitral valve prolapse; and to evaluate tolerability and
efficacy of beta-blockers in these patients.
METHODS
Between January 1999 and November 2000, 21
children with Marfan syndrome - 13 (62%) boys and 8
(38%) girls - were prospectively evaluated. Using the
reviewed criteria, the syndrome was confirmed in all the
patients9. Ages ranged from nine months to sixteenth years
(median 10 years). Patients’ body weight ranged from 8
to 70 kg. The study protocol was approved by the
Institutional Research Ethics Committee, and written
informed consent was obtained from all legal guardians
of the children for their inclusion in the study.
The same examiner performed all serial clinical and
echocardiographic examinations. A chest radiograph was
taken on the first visit and an electrocardiogram on each
follow-up visit. All patients were maintained on beta-
blocker medication, except those with any contrain-
dication; younger children received propranolol, and the
others received atenolol. Systemic blood pressure could
not be obtained in all children, and dosage of beta-blocker
was based solely on heart rate, that is to say, the necessary
dosage to maintain heart rate at around 60 bpm or the
maximum dosage of the drug for body weight. All school-
age children were instructed not to engage in competitive
physical activities.
Echocardiograms were performed using ATL HDI
1500, ATL 5000, or Phillips SD-800 machines equipped
with a 2.5 or 5 MHz electronic, multifrequency
transducers.  Heart cavities and aortic root measurements
(in the Valsalva sinuses area) were performed by two-
dimensional guided M-mode echocardiographs; only one
patient had aortic root measurement taken in two-
dimensional mode using the parasternal long-axis view
at end-diastole.
Mitral valve prolapse was defined by echocardiographic
examination using Freed et al’ criteria10 (superior
displacement of one or both mitral leaflets by more than
2 mm above the mitral annular plane during ventricular
systole on the parasternal long-axis view).
Mitral and aortic valve regurgitation was further divided
into two groups: mild or minor and significant (moderate
and severe) After gain adjustment and maximum increase
of Nyquist velocity,  reflux severity was assessed visually
and subjectively, taking into account morphological
changes of mitral valve, cavities measurements and
regurgitant jet into the left atrium11. Later, interobserver
analysis for the quantification of mitral regurgitation was
performed. Two experienced and independent examiners
reviewed images of ten examinations recorded on VHS
tape and, using the same method, determined the degree
of valve regurgitation.
Aortic regurgitation was estimated by the ratio of jet width
to the left ventricular outflow tract on color flow mapping11.
Annuloaortic ectasia grading was based on reference
values used by the Echocardiography Department
(adapted from Roge et al)12 and was established by weight
range following the criterion below: a) up to 20%, mild
enlargement; b) between 20 and 40%, moderate
enlargement; c) above 40%, major enlargement.
Both measurements were performed using the paired
Student’s t-test for correlated samples, in this case,
comparison of aortic root enlargement and heart rate behavior
during beta-block administration after one year, where p <
0.05 was considered significant. Interobserver variability of
mitral regurgitation was assessed by Kappa test.
RESULTS
All children remained asymptomatic during the one-
year follow-up, with no evidence of heart failure, including
the few with significant valve regurgitation. No
asymmetries were found on peripheral pulse palpation.
A two-year-old child underwent replacement of the
ascending aorta by the Bentall-De Bono technique, due
to severe annuloaortic ectasia with rapid enlargement of
the ascending aorta and worsening of aortic regurgitation.
Annuloaortic ectasia occurred in 16 (76%) patients
and found to be mild in 42.8%, moderate in 9.5%, and
severe in 23.8% (five children) (fig 1). Eleven (52%)
children had two measurements of the aortic root taken
one year apart. Mean annual increase of aortic diameter
was 10%, meaning 1.4 mm/year (p < 0.02) (tab I).
Only three children (14.2%) had aortic valve regurgitation,
with a mild regurgitation at the initial evaluation; however,
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Table I - Ages in months (m) or years (y); gender: male (M) or female (F); weight in kilograms; aortic diameter
(at Valsalva sinuses); and heart rate in beats per minute
Patient Age Gender Weight Aorta 1st meas. Aorta 2nd meas. Heart Rate 1 Heart Rate 2
1 9m M 8 26 mm 31 mm 150 100
2 7y F 22 54 mm 80 72
3 11y F 45 36 mm 37 mm 55
4 6y M 20 27 mm 28 mm 80 88
5 6y M 27 30 mm 66 55
6 10y M 52 45 mm 66 58
7 12y F 43 23 mm 56 54
8 10y M 70 34 mm 75
9 10y M 26 28 mm 26 mm 80 70
10 14y F 49 44 mm 46 mm 64
11 12y M 42 34 mm 98 58
12 16y M 69 38 mm 39 mm 67 48
13 13y M 38 34 mm 36 mm 55 60
14 5y F 20 21mm 80
15 1y M 20 25 mm 26 mm 118 110
16 14y M 38 43 mm 44 mm 115
17 10y F 23 43 mm 75
18 10y M 24 25 mm 27 mm 90 86
19 2y M 16 20 mm 21 mm 120 100
20 15y F 47 32 mm 70 54
21 8y M 25 27 mm 90
in one child the regurgitation evolved to a moderate-to-
severe degree.
Mitral valve heart murmur was heard in six (28.6%)
children, three of which were considered intense. Mitral
click was heard in 13 (61%) patients. On echocar-
diographic examination, 11 (52%) patients had valve
prolapse and 3 (14%) patients had significant mitral
regurgitation, one of which was deemed severe and the
other two moderate. In the interobserver analysis
performed later for assessment of mitral regurgitation, a
Kappa value of 0.635 was calculated, and as can be
seen in the corresponding table (table II), most differences
occurred in trivial regurgitation.
Beta-blocker therapy was attempted in all patients,
including two children with history of bronchial asthma;
this was tolerated by only one of them. Discontinuation
of therapy would be made only if necessary, such as in
case of bronchospasm. After beta-blocker therapy was
introduced, a decrease in mean hear rate was observed,
from 85 bpm to 73 bpm (p < 0.009) (table I).
DISCUSSION
Marfan syndrome is a hereditary disease caused by a
mutation in the gene for fibrillin located on chromosome
15. In 1972, Murdoch et al5 demonstrated the early
mortality of patients with Marfan syndrome between the
third and fourth decade of life. Moreover, the number of
deaths of patients under twenty years of age was not at
all negligible (25% of the total number of deaths of the
studied population). Cardiovascular death occurred in
93% of patients, most often secondary to aortic rupture,
dissection or insufficiency. Later, other studies showed a
significant improvement in survival afforded by advances
in diagnosis, clinical treatment and, especially, surgical
techniques.6 Recently, Gott et al13, emphasized the
importance of  elective surgery for annuloaortic ectasia,
with low operative mortality rates. Conversely, emergency
surgery was associated with a much higher mortality rate.
Although all patients of our series have remained
asymptomatic, a two-year-old child with neonatal Marfan
syndrome, the most severe form of the disease, required
replacement of the ascending aorta with a valved tube
(Bentall-De Bono technique)14. This child had already
presented for initial evaluation with a 26-mm aortic root
(the upper limit of normal for the child’s body weight should
be 17 mm) and mild aortic regurgitation. In a single year
the aortic root diameter increased 5 mm (19%), reaching
31 mm, followed by a worsening of aortic regurgitation.
Albeit asymptomatic, the child required surgical correction,
due to the impending risk of aortic rupture or dissection.
Currently, the child is in general good condition and taking
acetylsalicylic acid as the anti-platelet agent, because of
the mechanical aortic prosthesis.
Four other children with severe annuloaortic ectasia are
waiting for surgery. One of them required a concomitant
mitral valve repair for significant mitral regurgitation.
Earlier studies showed an incidence of mitral valve
prolapse of up to 100%15-16, yet rates are around 70% in
most publications17. In the present study, the incidence
of mitral prolapse was 52.4% (11 patients). This may be
partly explained by the stricter criteria used in our protocol.
Significant mitral regurgitation was detected in only 3
(14%) patients, and a single one was severe. The
incidence of annuloaortic ectasia was 76% (16 patients),
of which 23% was severe and, therefore, potentially more
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serious. While mitral regurgitation is usually progressive,
annuloaortic ectasia, despite also increasing over time,
can complicate abruptly once a significant degree of
dilation is reached, leading to catastrophic outcomes, such
as dissection or rupture. Eleven (52%) children had two
measurements of the aortic root taken one year apart.
Mean annual increase of aortic diameter was 10%, or
1.36 mm/year (p value p < 0.02).
In the study by Shores et al,18 which included adults
and adolescents, the ratio of aortic enlargement (measured
diameter divided by expected diameter) was 0.023 in
the treated group versus 0.084 in the control group. The
study showed an increase of 2.1 ±1.6 mm/year in the
non-treated group versus 0.7±1.8 mm/year and 1.1±1.1
mm/year in two groups of patients treated with atenolol
or propanolol, all of them with p < 0.0519.
 The faster rate of aortic root enlargement in our group
may be partly explained by the age range of the population
studied, since relative aortic root enlargement is higher
during childhood and adolescence than in adulthood, and
partly because, in our group, a child with the neonatal
form of Marfan syndrome accounted, alone, for a 5-mm
enlargement, representing 19% of the initial diameter.
Echocardiographic image of annuloaortic ectasia is
typical of Marfan syndrome (“pear-shaped”), with a greater
degree of dilation at the Valsalva sinuses and extending
to the sinotubular junction). Progressive dilation can
compromise the remainder of the ascending and the aortic
arch. Aortic root dilation also predispose both to a failure
of central coaptation and  aortic valve regurgitation20.
Although other authors also have reported changes in
the ascending aorta as the most serious lesions of Marfan
syndrome in children7-21-24, many textbooks on cardiology
still suggest that mitral valve lesions are the most
important in this pediatric group25, to some degree
because the research material included data of the time
in which the echocardiogram was not available26 as a
routine method to assess the aortic root. It is known that
plain chest radiograph alone does not allow a complete
evaluation of that portion of the aorta27. Several studies
pointing toward the mitral valve as the primary cause of
morbidity and mortality in the pediatric group were
conducted in children with the more severe, neonatal form
of the disease28, in which mitral valve prolapse with severe
regurgitation and intractable heart failure is more frequent29.
The beta-blocker used was atenolol, due to its easy
dosage regimen. Only a one-year-old child with a history
of bronchial asthma was given propranolol initially. The
bradycardiac response was both variable and
unpredictable. Some patients responded satisfactorily with
a heart rate around 60 bpm, whereas others, including
those on maximum dosage, got only modest results. An
asthmatic child tolerated beta-blocker therapy, with
discontinuation of medication only during bronchospasm
episodes. Even so, there was a decrease in average res-
ting heart rate, which dropped from 84 bpm to 73 bpm
(p < 0.009); minimum heart rate also dropped from 55
bpm to 48 bpm, and maximum heart went from 155
bpm to 115 bpm.
Some limitations of the study should be noted, such
as the relatively small number of patients included in the
sample and of those in whom two evaluations could be
made at a one-year interval, time that could be considered
too short; however, as children usually grow fast, the
variations observed may reflect the actual progressive
involvement of the aortic root in children with Marfan
syndrome. The mean enlargement of aortic root of 1.4
mm/year, though statistically significant to the group,
should be considered carefully, because variations about
1 mm may be observed in daily practice, with no clinical
significance. Nevertheless, it should be emphasized that,
at study conclusion, 76% of the patients had annuloaortic
ectasia, reference value for body weight considered.
Regardless of the limitations mentioned, the children
remained asymptomatic throughout the study, the use of
beta-blockers led to a significant reduction in heart rate,
and no significant adverse effects were observed.  Contrary
to the literature, the incidence of annuloaortic ectasia
was high (72%), greater than that of mitral valve prolapse
(52.4%), and an enlargement of 1.4 mm/year was
observed even during the effective use of beta-blockers.
Fig. 1 - Graphic distribution of individuals for annuloaortic ectasia
Table II - Interobserver analysis of the degree of
mitral regurgitation in 10 patients. A high level
of agreement is observed, with Kappa
statistics of 0.635
Mitral Regurgitation
Examiner Observer 1 Observer 2
1 Absent Absent Absent
2 Absent Absent Absent
3 Severe Severe Severe
4 Mild Mild Mild
5 Moderate Mild Moderate
6 Minimal Absent Absent
7 Minimal Minimal Absent
8 Mild Mild Minimal
9 Absent Absent Absent
10 Minimal Minimal Minimal
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